The Essential Resource for the Medical Design Engineering Community
Subscribe to MDT Magazine All

Biotel, Inc. Announces Definitive Merger Agreement With CardioNet, Inc.

November 8, 2010 4:33 am | by Bio-Medicine.Org | News | Comments

EAGAN, Minn., Nov. 8, 2010 /- CardioNet, Inc. (Nasdaq: BEAT ), a leading wireless medical technology company with an initial focus on the diagnosis and monitoring of cardiac arrhythmias, announced today that the Company entered into a definitive merger agreement with Biotel, Inc. (OTC...


Post-menopausal women over 40 needed for dry eye study

November 8, 2010 3:35 am | by Baylor College of Medicine | News | Comments

Women over the age of 40 who are past menopause can take part in a research study evaluating omega-3 fatty acids or fish oil as a treatment for dry eye. Dry eye is one of the most prevalent eye conditions in the United States, said Dr. Stephen Pflugfelder , professor of ophthalmology at...


Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2011 Financial Results

November 8, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

BETHESDA, Md., Nov. 8, 2010 /PRNewswire-Asia/ -- Chindex International, Inc. (Nasdaq: CHDX ), a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced financial results for the second quarter and first half of...


Parascript Awarded $244,479.25 Affordable Care Act Grant From the U.S. Government

November 8, 2010 3:35 am | by Bio-Medicine.Org | News | Comments

LONGMONT, Colo., Nov. 8, 2010 /- Parascript, LLC, the image analysis and pattern recognition technology provider, today announced that it was awarded a cash grant of $244,479.25 under the U.S. Government's Affordable Care Act. Under this act, the therapeutic discovery project program...


Biodel to Present Data from Product Development Programs at 2010 Diabetes Technology Meeting

November 8, 2010 3:34 am | by Bio-Medicine.Org | News | Comments

DANBURY, Conn., Nov. 8, 2010 /-  Biodel Inc. (Nasdaq: BIOD ) announced today that the following abstracts describing recent findings from the company's product development programs have been accepted for poster presentation at the Tenth Annual Diabetes Technology Meeting in Bethesda,...


TTI: The Big Job-"Robotti Campaign Speech"

November 8, 2010 3:32 am | by ttithebigjob | Videos | Comments

Need Help Affording Your Meds? LegitScript Adds Patient Assistance Feature

November 7, 2010 10:32 pm | by Bio-Medicine.Org | News | Comments

PORTLAND, Oregon, Nov. 8, 2010 /- A leading Internet pharmacy verification service offers a new message for patients: There are ways to get affordable medicines without using unregulated, potentially dangerous "rogue" Internet pharmacies. LegitScript, a firm that monitors "rogue" Internet...


WuXi PharmaTech Awarded GLP Certificate from SFDA for Suzhou Toxicology Facility

November 7, 2010 10:32 pm | by Bio-Medicine.Org | News | Comments

SHANGHAI, Nov. 8, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech (NYSE: WX ), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced that it had been awarded a Certificate of Good...


Combating Childhood Cancer

November 7, 2010 10:31 pm | by San Diego Business Journal | News | Comments

Beth Anne Baber believes the intellectual capital, business acumen and philanthropic potential in San Diego provide the ideal environment to support the growth of a new institute that focuses on pediatric cancer research, diagnosis and treatment.


Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent

November 7, 2010 8:35 pm | by Bio-Medicine.Org | News | Comments

RESEARCH TRIANGLE PARK, N.C., Nov. 7, 2010 /- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today reaffirmed its commitment to the dual development of CMX001 as a medical countermeasure against smallpox and as a broad-spectrum antiviral...


Harvard's headache cure: LSD?

November 7, 2010 8:34 pm | by Mass High Tech: The Journal of New England Technology | News | Comments

Move over, Advil. Harvard Medical School researcher John Halpern says LSD, the hallucinogen at the heart of the 1960s drug counterculture, holds a better treatment for cluster headaches, and he's formed a company he hopes will bring to market a drug based on his research.


Futures in Biotech 70: SBIR Funding: The Business of Science

November 7, 2010 4:35 pm | Podcasts | Comments

Host: Marc Pelletier How to fund the development of your own technology through SBIR funding. Guest: Lisa Kurek of Biotechnology Business Consultants We invite you to read, add to, and amend our show notes. Comments and suggestions on Futures in Biotech. For a free audiobook, visit...

In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Ph...

November 7, 2010 4:33 pm | by Bio-Medicine.Org | News | Comments

NEW YORK, Nov. 7, 2010 /- Pfizer Inc. (NYSE: PFE ) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically...


Studying the metabolome of smokers, Lombardi researchers find early signs of damage

November 7, 2010 7:32 am | by EurekAlert | News | Comments

(Georgetown University Medical Center) Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi...


APHA 2010: Health-care reform and people with disabilities

November 6, 2010 8:33 pm | by EurekAlert | News | Comments

(Indiana University) Federal health-care reform holds the promise of more independent lives for people with disabilities. While a repeal of the law will be difficult, not funding elements could have the same impact as a repeal, says Heather A. McCabe, J.D., with Indiana...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.